GSK’s B7-H3 ADC secures EU orphan drug status as it accelerates global lung cancer trials

Venkatesh- October 30, 2025 0

GSK’s B7-H3-targeted ADC GSK’227 receives EU Orphan Drug Designation for small-cell lung cancer. Learn how it fits into the company’s expanding global trial program. Read More

How AnaptysBio’s 2026 spin-off plan could reshape its pipeline, royalty flows, and stock outlook

Pallavi Madhiraju- September 30, 2025 0

Discover how AnaptysBio (NASDAQ: ANAB) plans to split into two focused companies to unlock hidden value and reshape its investment story. Read More

Enanta Pharmaceuticals to reveal Phase 2b RSV trial results—can zelicapavir change treatment for high-risk adults?

Pallavi Madhiraju- September 28, 2025 0

Enanta Pharmaceuticals will present Phase 2b zelicapavir results in RSV high-risk adults. See why this trial matters for investors, patients, and the RSV market. Read More

Is pharma nationalism reshaping global R&D? What GSK, Eli Lilly, and AstraZeneca are signaling to the world

Pallavi Madhiraju- September 25, 2025 0

GSK, Eli Lilly and AstraZeneca are reshaping global pharma strategy with massive U.S. investments—find out what this means for R&D, supply chains, and policy. Read More

Why GSK is investing $30bn in the U.S. now—and what it means for global pharma manufacturing

Pallavi Madhiraju- September 17, 2025 0

GSK to invest $30B in U.S. R&D and manufacturing amid trade policy shifts—find out how this shapes global pharma supply chains and investor sentiment. Read More

Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk

Pallavi Madhiraju- November 7, 2024 0

In a crucial development for public health, Health Canada has extended its approval for GlaxoSmithKline's Arexvy vaccine to include adults aged 50 to 59 who ... Read More

Pfizer to offload 540 million shares in shocking Haleon sale—What does this mean for the healthcare giant?

Pallavi Madhiraju- September 30, 2024 0

In a blockbuster move set to shake up the market, Pfizer has announced its plan to sell approximately 540 million ordinary shares in Haleon, one ... Read More

Glenmark Pharmaceuticals gets FDA final approval for Compazine generic

Pallavi Madhiraju- March 20, 2023 0

Glenmark Pharmaceuticals has bagged final approval for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg from the US Food & Drug Administration (FDA). The ... Read More

Strides Pharma gets FDA approval for Ibuprofen oral suspension

Srinath- June 11, 2022 0

Strides Pharma Science Limited said that its stepdown fully-owned subsidiary — Strides Pharma Global Pte. Limited, Singapore, has secured approval from the US Food and ... Read More

GSK to acquire vaccine developer Affinivax in deal worth up to $3.3bn

Srinath- June 1, 2022 0

GlaxoSmithKline (GSK) has agreed to acquire Affinivax, a Boston-based clinical-stage vaccine developer, in a deal worth up to $3.3 billion. The consideration includes an upfront ... Read More